"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in Harvard Catalyst Profiles by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 |
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 3 | 4 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 3 | 6 |
| 2010 | 4 | 6 | 10 |
| 2011 | 9 | 8 | 17 |
| 2012 | 6 | 2 | 8 |
| 2013 | 9 | 5 | 14 |
| 2014 | 5 | 6 | 11 |
| 2015 | 4 | 5 | 9 |
| 2016 | 9 | 4 | 13 |
| 2017 | 5 | 4 | 9 |
| 2018 | 1 | 3 | 4 |
| 2019 | 4 | 7 | 11 |
| 2020 | 4 | 8 | 12 |
| 2021 | 0 | 5 | 5 |
| 2022 | 1 | 15 | 16 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes Care. 2023 Jan 01; 46(1):65-74.
-
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. Cardiovasc Ther. 2022; 2022:6820377.
-
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989.
-
In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system. Cell Chem Biol. 2022 09 15; 29(9):1368-1380.e5.
-
Association of GLP1R Polymorphisms With the Incretin Response. J Clin Endocrinol Metab. 2022 08 18; 107(9):2580-2588.
-
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study. Am J Epidemiol. 2022 Jul 23; 191(8):1352-1367.
-
Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity. Clin Nutr. 2022 09; 41(9):1969-1976.
-
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022 10; 23(5):979-994.
-
Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease. Lipids. 2022 07; 57(4-5):241-255.
-
IL18 signaling causes islet ß cell development and insulin secretion via different receptors on acinar and ß cells. Dev Cell. 2022 06 20; 57(12):1496-1511.e6.